The lancet oncology
-
The lancet oncology · Jun 2012
Randomized Controlled Trial Multicenter Study Comparative StudyChemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.
Fluorouracil-based chemoradiotherapy is regarded as a standard perioperative treatment in locally advanced rectal cancer. We investigated the efficacy and safety of substituting fluorouracil with the oral prodrug capecitabine. ⋯ Roche Pharma AG (Grenzach-Wyhlen, Germany).
-
The lancet oncology · Jun 2012
Multicenter Study Clinical TrialFocal therapy for localised unifocal and multifocal prostate cancer: a prospective development study.
Radical whole-gland therapy can lead to significant genitourinary and rectal side-effects for men with localised prostate cancer. We report on whether selective focal ablation of unifocal and multifocal cancer lesions can reduce this treatment burden. ⋯ Medical Research Council (UK), Pelican Cancer Foundation, and St Peters Trust.
-
The lancet oncology · Jun 2012
Review Comparative StudyGlobal burden of cancers attributable to infections in 2008: a review and synthetic analysis.
Infections with certain viruses, bacteria, and parasites have been identified as strong risk factors for specific cancers. An update of their respective contribution to the global burden of cancer is warranted. ⋯ Fondation Innovations en Infectiologie (FINOVI) and the Bill & Melinda Gates Foundation (BMGF).
-
The lancet oncology · Jun 2012
Review Comparative StudyLenalidomide maintenance for multiple myeloma.
-
The lancet oncology · Jun 2012
ReviewOptimising radiation treatment decisions for patients who receive neoadjuvant chemotherapy and mastectomy.
Whereas randomised clinical trials have established which patients might benefit from postmastectomy radiation therapy after upfront surgery, no such data exist for guiding decisions on who might benefit from postmastectomy radiation therapy after upfront chemotherapy. Insight must be drawn from non-randomised data to provide such guidance. Early data suggest that both extent of disease at presentation and response to neoadjuvant chemotherapy predict the risk of locoregional recurrence, and can be used to tailor recommendations for postmastectomy radiation therapy. Randomised clinical trial data are needed to assess whether postmastectomy radiation therapy can be safely omitted in selected women with good response to neoadjuvant chemotherapy.